Related Experiment Video

Updated: May 31, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594

Caroline J Breitbach1, Steve H Thorne, John C Bell

  • 1Jennerex Inc. San Francisco, CA, USA. cbreitbach@jennerex.com

Current Pharmaceutical Biotechnology
|July 12, 2011
PubMed

Insights

Oncolytic viruses like JX-594 show promise for treating metastatic cancers. This engineered vaccinia virus targets tumors and stimulates immunity, demonstrating potent efficacy in clinical trials.

Area of Science:

  • Virology
  • Immunology
  • Oncology

Background:

  • Oncolytic viruses (OVs) are engineered to selectively infect and kill cancer cells.
  • JX-594 is a novel oncolytic poxvirus derived from vaccinia virus, designed for enhanced tumor targeting and armed with granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • Poxviruses offer advantages for oncolysis, including a robust safety profile from smallpox eradication and potential for systemic spread to treat metastatic disease.

Purpose of the Study:

  • To review preclinical and clinical data for JX-594, an oncolytic poxvirus.
  • To evaluate the efficacy and safety of JX-594 in patients with treatment-refractory metastatic cancers.

Main Methods:

  • Review of preclinical studies demonstrating JX-594's cancer selectivity and systemic efficacy.
  • Analysis of Phase 1 and 2 clinical trial data assessing JX-594's performance in patients with advanced cancers.

Main Results:

  • Preclinical studies confirmed JX-594's high cancer selectivity and multi-mechanism systemic efficacy.
  • Clinical trials demonstrated potent and systemic anti-tumor activity of JX-594 in patients with refractory metastatic cancers.

Conclusions:

  • JX-594 exhibits significant potential as an oncolytic agent for metastatic cancers.
  • The engineered poxvirus JX-594 shows promising efficacy and systemic activity, supporting its further development in cancer therapy.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...